MYC-Driven Tumorigenesis Is Inhibited by WRN Syndrome Gene Deficiency

Russell Moser, Masafumi Toyoshima, Kristin Robinson, et al.


Updated Version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-11-0508

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2012/02/01/1541-7786.MCR-11-0508.DC1.html

Cited Articles
This article cites 36 articles, 19 of which you can access for free at:
http://mcr.aacrjournals.org/content/10/4/535.full.html#ref-list-1

Citing Articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://mcr.aacrjournals.org/content/10/4/535.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.
DNA Damage and Cellular Stress Responses

MYC-Driven Tumorigenesis Is Inhibited by WRN Syndrome Gene Deficiency

Russell Moser1, Masafumi Toyoshima1, Kristin Robinson1, Kay E. Gurley1, Heather L. Howie1, Jerry Davison2, Martin Morgan2, Christopher J. Kemp3, and Carla Grandori1,3

Abstract

MYC-induced DNA damage is exacerbated in WRN-deficient cells, leading to replication stress and accelerated cellular senescence. To determine whether WRN deficiency impairs MYC-driven tumor development, we used both xenograft and autochthonous tumor models. Conditional silencing of WRN expression in c-MYC overexpressing non–small cell lung cancer xenografts impaired both tumor establishment and tumor growth. This inhibitory effect of WRN knockdown was accompanied by increased DNA damage, decreased proliferation, and tumor necrosis. In the Eμ-Myc mouse model of B-cell lymphoma, a germline mutation in the helicase domain of Wrn (WrnΔhel/Δhel) resulted in a significant delay in emergence of lethal lymphomas, extending tumor-free survival by more than 30%. Analysis of preneoplastic B cells from Eμ-Myc Wrn mutant mice revealed increased DNA damage, elevation of senescence markers, and decreased proliferation in comparison with cells from age-matched Eμ-Myc mice. Immunohistochemical and global gene expression analysis of overt Eμ-Myc WrnΔhel/Δhel lymphomas showed a marked increase in expression of the CDK inhibitor, p16Ink4a, as well as elevation of TAp63, a known mediator of senescence. Collectively, these studies show that in the context of Myc-associated tumorigenesis, loss of Wrn amplifies the DNA damage response, both in preneoplastic and neoplastic tissue, engaging activation of tumor suppressor pathways. This leads to inhibition of tumor growth and prolonged tumor-free survival. Targeting WRN or its enzymatic function could prove to be an effective strategy in the treatment of MYC-associated cancers. Mol Cancer Res; 10(4); 535–45. ©2012 AACR

Introduction

We previously showed that WRN, a gene encoding a RecQ DNA helicase, is a direct transcriptional target of c-MYC, and that the absence of WRN causes MYC overexpression, h-Tert immortalized cells to undergo senescence (1). Mechanistically, the MYC/WRN codependence has been explained by the recent demonstration that MYC directly influences the DNA prereplication machinery, and that MYC overexpression dramatically accelerates S-phase, thereby sensitizing cells to “replication stress” (2). Inhibition of WRN function in MYC overexpressing cells leads to excessive accumulation of DNA damage at sites of newly repli-

cated DNA, triggering activation of the ATR–CHK1 pathway and, in turn, forcing the cells into a nonproliferative, senescent state (3). Thus, MYC transcriptional stimulation of the WRN gene provides a feed-forward mechanism to limit MYC-associated DNA replication stress and enables continued cell proliferation.

Mutations in the WRN gene are associated with a progeroid syndrome in humans [Werner syndrome (WS)], which is characterized by accelerated aging, cellular senescence, genomic instability, and an increased incidence of otherwise rare cancers of mesenchymal origin (4, 5). WRN encodes a multifunctional protein with both DNA helicase and exonuclease activity, a property which sets WRN as the exception among other members of the RecQ family, which harbor only a DNA helicase domain (6, 7). WRN protein binds to and modifies DNA secondary structures that are likely to arise during DNA replication (8, 9). This property of WRN protein is consistent with its role in repair/recovery from replication-associated damage (10, 11). The role of WRN in maintaining DNA fidelity, coupled with the tumor predisposition of WS patients, suggested that WRN could function as a tumor suppressor gene. However, WRN mutations have not been reported in tumors, and we and others have found that WRN and other members of the RecQ helicase family are significantly overexpressed in cancer cell lines derived from Burkitt’s lymphoma, neuroblastoma, breast, ovarian, and lung cancers (C. Grandori;
unpublished results and ref. 12). Furthermore, whereas fibroblasts from Wrn mutant mice exhibit enhanced sensitivity to DNA cross-linking agents, characteristic of human WS cells (13, 14), Wrn-deficient mice have not shown a predisposition to spontaneous tumor development. These observations, together with the prosurvival role of WRN in MYC overexpressing cells, suggest WRN could play a supporting role in the context of MYC-dependent tumorigenesis and consequently, its deficiency might inhibit rather than accelerate tumor development. Here, we establish that acute WRN depletion in MYC overexpressing human lung cancer xenografts blocks tumor growth and further, that germline Wrn deficiency in mice causes a significant delay in Myc-induced lymphomagenesis and prolongs tumor-free survival. Thus, in the context of Myc-driven cancers, Wrn provides a critical prosurvival function that is necessary for efficient tumor growth and constitutes a candidate druggable target in tumors driven by an “undruggable” oncogenic driver.

Materials and Methods

Mouse strains, genotyping, and tumor monitoring

The Wrn<sup>Δmel/mel</sup> mutation (14) was backcrossed onto C57BL/6 mice to purity (N20). The C57BL/6 Eμ-Myc transgenic mouse strain (15) was interbred to C57BL/6 Wrn<sup>Δmel/mel</sup> mice to generate Eμ-Myc Wrn<sup>Δmel/+</sup> and Wrn<sup>Δmel/+</sup> mice, which were subsequently intercrossed and backcrossed to parental lines to generate nontransgenic and Eμ-Myc transgenic Wrn<sup>+/+</sup> and Wrn<sup>Δmel/Δmel</sup> experimental animals (F1 generation). Mice were monitored daily for signs of morbidity and tumor development. Moribund animals were sacrificed and tumors and lymphoid organs were harvested for histopathologic and molecular analysis. Germ-line transmission of the Eμ-Myc transgene, and the Werner helicase domain deletion (WrnΔd exon 3–4) was confirmed using conventional PCR–based genotyping strategies (14, 15). All animal protocols were approved by the Fred Hutchinson Cancer Research Center Laboratory Animal Care and Use Committee.

Immunoblotting of lymphomas

Whole cell protein extracts from primary pre-B cells and B-cell tumors from Eμ-Myc and Eμ-Myc Wrn<sup>Δmel/mel</sup> transgenic mice were isolated as previously described (16). Equal amounts of clarified lysates (100–150 μg per lane) were analyzed by Western blotting with antibodies specific to mouse p19Arf (5–C3–1), p16Ink4a (M-156), Mdm2 (C-18) pAb, and Actin (I-19) from Santa Cruz Biotechnology, Mdm2 (MD-219-Abcam) mAb, Cyclin D1 (DCS6), pH2A.X (ser139), pAtr (ser424) p53 (ser18), and cleaved caspase-3 (Asp175) from Cell Signaling Technology, and p53 (CM5) from Novocstra. Detection was by enhanced chemiluminescence (Supersignal–Thermo Scientific).

Acidic β-galactosidase assay

The senescence-associated β-galactosidase assay (SA-β-gal) was carried out as previously described with some modifications (17, 18). Briefly, murine tissues were harvested and frozen gradually (CO2) in cryomolds within OCT compound and stored at −80°C. Cryosections of tissues were cut using a cryotome at 6 to 12 μm, fixed in 0.5% glutaraldehyde (6-μm section/15 minutes) at room temperature (22°C), and rinsed with PBS (pH 7.3). Tissue sections were then covered with fresh SA-β-gal stain [40 mmol/L citric acid/sodium phosphate (pH 6.0), 1 mg/mL Xgal (DMF), 5 mmol/L potassium ferricyanide, 5 mmol/L ferrocyanide, 150 mmol/L NaCl, 2 mmol/L MgCl2] placed in humidity chambers, and incubated at 37°C in an ambient 21% O2 environment for 6 to 8 hours. After staining, tissue sections were rinsed with PBS and processed via standard immunohistochemical protocols.

Flow cytometric analysis of B-cell proliferation and apoptosis

Single-cell suspensions of bone marrow cells and splenocytes were prepared by harvesting marrow from femurs, dissociating the spleens between frosted microscope slides and filtering both cell preparations through nylon cell strainers. For analysis of differentiation status, splenic cells were incubated with PE-conjugated anti-CD45R/B220 and PerCP-Cy5.5–conjugated anti-IgM antibodies (BD Biosciences Pharmingen). Proliferation rates were measured using a fluorescein isothiocyanate (FITC) 5-bromo-2-deoxyuridine (BrdUrd) Flow Kit (BD Biosciences Pharmingen) as described by the manufacturer. Animals were injected with BrdUrd (40 mg/gram body weight, intraperitoneally), and bone marrow and spleen were harvested 2 hours later. Apoptosis in pre-B (B220+/IgM+) and B-cell (B220+/IgM+) populations from spleen and bone marrow was measured using FITC-conjugated antiangiactase-3 (BD Biosciences Pharmingen). All samples were analyzed by a FACSCalibur (Becton-Dickinson).

Splenocyte isolation and immunoblotting

Single-cell suspensions were generated from spleens of Eμ-Myc and Eμ-Myc Wrn<sup>Δmel/mel</sup> mice as previously described (19). Cell suspensions were suspended in a hypotonic buffer to lyse red blood cells, and splenic lymphocytes and cellular debris were separated via centrifugation along a ficoll-hypaque (d = 1.077) gradient (800 × g at 4°C for 15 minutes). Isolated splenocytes were then lysed in 50 mmol/L Tris (pH 8.0), 200 mmol/L NaCl, 5 mmol/L EDTA, 1% Triton X-100, 10% Glycerol, 1 mmol/L NaVO 4, 2 mmol/L DTT, 1.5 μg/mL aprotinin, 0.3 mg/mL pefabloc, 6 μg/mL leupeptin. Equal amounts of clarified protein lysates (50 μg per lane) were analyzed by Western blotting with antibodies to phospho-H2AX (Serine 139), phospho-Atr (Serine 428), phospho-p53 (Serine18) from Cell Signaling Technology, p53 (CM5) from Novocstra, and β-Actin from BioVision.

Sequence analysis of lymphomas

Total RNA was isolated from select lymphomas using TRIzol (Invitrogen) followed by Qiagen RNaseqy Mini Kit (Qiagen). The first strand cDNA was synthesized with dT oligos from Superscript III first strand kit (Invitrogen). p53
cDNA was amplified using the primer set for exons 2–11 (p53-fwd: 5’-GCTTGTCCTCGGAAAAGTGTGACT-3’ and p53-rev: 5’-GTTTGGTCTGTCAGCCCTGAAAGTCA-3’; ref. 20). A second primer set for exons 5–8 (p53-fwd:Ex5: 5’-GTACC TTAAGGACCCCGA-3’ and p53-rev:Ex8: 5’-TTTTCTTCTTCGCGGGA-3’) were used for confirmation of sequence fidelity. PCR products were sequenced via ABI 3730xl DNA Analyser (Applied Biosystems) using the same primer sets. Sequencing data were aligned to Mus musculus p53 mRNA transcript sequences [ENSMUSP00000104298, . . . 104297, . . . 005371; www. ensembl.org]. Biallelic deletions of the Cdkn2a (Ink4a/ARF) locus were also examined from select lymphomas via PCR of genomic exons 1α, exon1β, exon 2, and exon 3.

Immunohistochemical staining of lymphomas

Tissues were fixed in normal buffered formalin (NBF), processed to paraffin and stained for hematoyxin and eosin (H&E), specific proteins, BrdUrd, or terminal deoxynucleotidyl transferase dUTP end labeling (TUNEL). Staining for p53 (Vector), p19Arf (Santa Cruz), Histone H3 (Serine10; Cell Signaling Technology), Histone H2A.X (Serine13; Cell Signaling Technology), and cleaved caspase-3 (Cell Signaling Technology) were done using a standard 3-step ABC method. Slides were developed using DAB/NiCl (Sigma) and counterstained with methyl green. Sections for BrdUrd (Dako) staining were treated with HCl and trypsin (Sigma) and counterstained with methyl green. Sections for BrdUrd (Dako) staining were treated with HCl and trypsin before incubating with primary antibody. For TUNEL staining, Trevigen TACS2 TdT kit was used as per manufacturer’s instructions.

Expression analysis and in vitro assay of Wrn-mediated knockdown

RNA was extracted from mouse tissue using the RNAeasy RT Kit (Qiagen), reverse transcribed using the Superscript II kits (Invitrogen). The following probe sets were used in the expression analysis: the Bioconductor package limma was used for multiple testing corrections using Benjamini and Hochberg procedure. The Bioconductor package limma was used to carry out the modified t statistic significance testing (23) and multiple testing corrections using Benjamini and Hochberg (24). All microarray data (MIAME compliant) are deposited in NCBI’s Gene Expression Omnibus (25) and are accessible through GEO Series accession number (GSE25671).

Lentiviral shRNA construction and packaging

Lentiviral constructs for each short hairpin RNA (shRNA) and a scramble were designed and constructed in a pLenti6- tts system using the Gateway LR Clonase. Stbl3 chemically competent cells (Invitrogen) were transformed with 1 to 5 ng of DNA, and clones were selected on blasticidin (50 µg/mL) LB isolated, screened, and propagated. 293FT cell line (derived from 293F cells, stably expressing the SV40 large T antigen for enhanced virus production) was cultured in DMEM/10% FBS/500 µg/mL G418/pen/strep ViraPower Packaging Mix (Invitrogen) and suspended in 195 µL of sterile water to a concentration of 1 µg/µL. When coinfected with the plenti-DEST expression construct into the 293FT producer cell line, this mixture of plasmids supplies the viral proteins in trans that are required to create viral products. Viral supernatants were generated using 293FT cells transfected with 10 µg shRNA plasmid using Lipofectamine 2000 and the appropriate lentiviral packaging plasmid DNA (ViraPower). The media was changed 16 hours after transfection.
after transfection and the virus was harvested 48 to 56 hours later. Viral supernatant was filtered (0.40 µm), aliquotted and frozen at −80 for subsequent use.

**Lentiviral mediated knockdown of WRN protein in A549 lung carcinoma cells**

Human A549 small cell lung carcinoma cells (American Type Culture Collection) cultured in DMEM/10%FBS/pen/strep were infected with lentiviral tet-mediated vectors with shRNA scramble control (19-mer–GUUGUUCUA-CUUCUCGUGG), shWRN-I (19-mer–GUCUA-CGCGUGUAGCAAU), shWRN-II (19-mer–GUC-CUUAUCCCAUGGCA), or shWRN-III (19 mer–GAGACAAAUAUCUUUGCU) 5′–3′ target sequences and knockdown of the WRN protein was assessed via immunoblot 48 hours posttreatment with 0.01 µg/mL doxycycline (Sigma D9891) in culture media. Immunoblots were probed with WRN pAb (H-300), Actin (I-19), and c-Myc (N-262) antibodies purchased from Santa Cruz Biotechnology.

**Xenograft tumor models**

A549 cells were Freshly infected with either the lentiviral tet-mediated shRNA scramble control or the shWRN-I (Fig. 1E and F) or shWRN II (Fig. 1G and H) and 2.5 × 10⁶ cells in 0.2 mL PBS were inoculated subcutaneously into the left and right flanks of 10 eight-week-old nonobese diabetic–severe combined immunodeficient (NOD-SCID) gamma null mice, respectively. For the experiment of Fig. 1E and F (shWRN I), FOXN1 (nu/nu) nude mice were exposed to doxycycline from day 1. For the experiment of Fig. 1G and H (shWRN II), NOD-SCID gamma null mice were given doxycycline (2 mg/mL in 5% sucrose) *ad libitum* in their drinking water (*n* = 5), only when tumors had reached a visible size, whereas an equal number of mice received only 5% sucrose water. The volume of the implanted tumor was measured every 2 to 3 days with a caliper, using the formula: \( V = L \times W^2/2 \); in which \( V \), volume (mm³); \( L \), biggest diameter (mm); \( W \), smallest diameter (mm). A tumor was defined as a palpable mass of 100 mm³ or more volume. Mice were sacrificed at 3 to 4 weeks.

**Statistical analysis**

All images shown are representative of at least 10 fields viewed over 2 stained sections per animal. Quantitation was done using 10 fields per animal. All columns represent mean ± SEM, unless otherwise noted. All statistical analyses were done using unpaired 2-tailed *t* test unless otherwise indicated. Statistical analysis of Kaplan–Meier survival curves was done via log-rank (Mantel–Haenszel) test (Graphpad Software) or SPSS (IBM, Worldwide).

**Results**

**WRN is critical for establishment and growth of non–small cell lung cancer cells with MYC overexpression**

To examine the role of WRN in a model of Myc-associated cancer, the growth rates of A549 non–small cell lung carcinoma (NSCLC) xenografts were monitored after WRN knockdown. A549 cells express high levels of c-MYC, as confirmed via Western blot analysis (Fig. 1A). Three shRNAs against WRN were first tested in transient assays in 293T cells. shWRN I and shWRN II indicated the best knockdown (data not shown). A549 cells were transduced with lentivectors expressing doxycycline-conditional shWRN I or shWRN II specific to the WRN gene. Knockdown was measured by Western blot analysis (Fig. 1B) and through a time course of WRN mRNA following shWRN I (Fig. 1D). The latter indicated that optimal knockdown occurred several days after shRNA induction, consistent with the long half-life of WRN protein and mRNA. To determine the effect of WRN depletion on the growth of A549 cancer cells, long-term colony assays were carried out. In A549 cells harboring a control shRNA, growth was not affected by doxycycline treatment, whereas cells expressing the WRN-specific shRNA showed a dramatic inhibition of growth following addition of doxycycline (Fig. 1C). We next wished to test the role of WRN in tumor establishment and growth in 2 xenograft models. One, in which expression of the shRNA was initiated at the time of tumor cell injection, and a second, a therapeutic model in which tumors were established before WRN knockdown. Figure 1F shows the tumor size over time in 4 mice, in which each mouse was injected on one flank with A549 cells transduced with a control shRNA and on the other with shWRN I. Mice were exposed to doxycycline from the day of implantation to induce shRNA expression. A representative mouse showing inhibition of tumor growth by WRN knockdown is shown in Fig. 1E. The results obtained with the therapeutic model are shown in Fig. 1G and H, in which 10 mice (5 in each arm sh control and shWRN II) were exposed to doxycycline after tumors reached approximately 100 mm³. In this therapeutic model, A549 tumor growth was markedly inhibited by shWRN II induction. Representative xenografts are shown in Fig. 1G. Thus WRN deprivation with 2 different hairpins in 2 settings markedly inhibited tumor establishment and growth. WRN-depleted xenografts displayed a prominent increase in DNA damage, an increase in necrosis, and a reduction in proliferative cells (Fig. 2A and B). However, no significant difference in caspase-3–dependent apoptosis compared with controls was observed (Fig. 2C). Together, these results established that impaired tumor growth caused by WRN depletion is due to increased DNA damage and reduced proliferation.

**Wrn deficiency delays Eμ–Myc–induced lymphomagenesis and prolongs tumor-free survival**

As the immune system and tumor microenvironment profoundly affect tumor development, we next addressed the role of Wrn in an autochthonous model of tumorigenesis in immunocompetent mice. To this end, we assessed the impact of a germline Wrn helicase mutation (Wrn*hel/hel*; ref. 14) on tumor latency in the Eμ–Myc mouse model. Eμ–Myc mice constitutively express c-myc in lymphoid precursor cells, leading to pre-B cell hyperplasia and subsequent lymphoma development (15). Cohorts of Eμ–Myc (*n* = 41),
Em-Myc mice (n = 50), as well as wild-type (n = 30) and WrnAΔdelΔsel (n = 30) mice were followed for more than 2 years and Kaplan–Meier survival curves were generated. Virtually all Em-Myc mice developed lymphomas, but the median latency in Em-Myc WrnAΔdelΔsel mice (151 days) was significantly delayed relative to Em-Myc mice (115 days; Fig. 3A). Control wild-type and WrnAΔdelΔsel mice did not develop any related pathology over the same timespan (data not shown). To confirm the transcriptional induction of WRN by c-Myc overexpression, previously
observed in vitro (1), Wrn protein and mRNA expression was measured in normal spleen and lymphomas from Eµ-Myc mice. Wrn protein levels were indeed elevated in both preneoplastic and lymphoma-derived cells from Eµ-Myc mice (Supplementary Fig. S1). In addition, expression of the truncated Wrn protein was verified in tissues from Wrn−/− mice (Supplementary Fig. S2). Together, these results highlighted a protumorigenic role for the Wrn DNA helicase in a well-documented model of Myc-driven tumorigenesis.

Wrn deficiency triggers a DNA damage response leading to proliferation arrest in the preneoplastic stage of tumor development

To address the basis for the impaired lymphomagenesis in Eµ-Myc Wrn−/− mice, we established another mouse cohort to examine markers of proliferation, apoptosis, and DNA damage in preneoplastic splenocytes before emergence of lymphomas. Preneoplastic B cells isolated from both bone marrow and spleen from Eµ-Myc Wrn−/− mice showed reduced proliferation compared with Eµ-Myc mice (Fig. 3B). Quantification of cleaved caspase-3–positive cells indicated that apoptosis was not significantly elevated in Wrn-deficient preneoplastic cells (Fig. 3C). Analysis of cell surface markers indicated that Wrn deficiency does not impinge on B cell homeostasis, as judged by the similar ratio of pre-B cell precursors versus mature B cells in Eµ-Myc mice from both Wrn genotypes (Fig. 3D). Consistent with reduced proliferation markers and the known role of Wrn in cellular senescence, a prominent increase in senescence-associated β-galactosidase (SA-β-gal) staining was observed in preneoplastic B-cell compartments (germinal center follicles of the spleen) from Eµ-Myc Wrn−/− mice compared with Eµ-Myc mice (Fig. 3E). Longitudinal immunoblot analysis indicated an increase in the accumulation of γ-H2AX (Serine 139), Atr (Serine 428), and p53 (Serine 18) in preneoplastic splenocytes from Eµ-Myc Wrn−/− mice (Fig. 3F). Thus, Wrn deficiency blocks the expansion of preneoplastic cells by triggering a DNA damage response that impairs cell proliferation and favors senescence, thereby delaying the emergence of overt tumors.

Wrn deficiency delays lymphomagenesis by engaging tumor suppressor pathways

Previous research using the Eµ-Myc mouse model has shown that development of lymphomas coincides with either biallelic deletions in the Cdkn2a locus or mutation in the p53 tumor suppressor (16, 26, 27). To further elucidate the mechanism by which Wrn deficiency delays lymphomagenesis, p53, p19ARF, p16INK4a, cyclin D1, and cleaved caspase-3 were examined in Eµ-Myc and Eµ-Myc Wrn−/− lymphomas. We observed a striking elevation of the cyclin-dependent kinase (CDK) inhibitor p16INK4a in the majority of Eµ-Myc Wrn−/− (82%) compared with Eµ-Myc (33%) lymphomas (Fig. 4A, Supplementary Fig. S3A, *P = 0.006). p16INK4a normally functions to sequester Cdk4, allowing for the degradation of cyclin D1 and release of p27KIP1 from cyclin D1–Cdk4 complexes. Ultimately, this engages a G1 cell-cycle arrest through Rb activation (28). Consistent with this role for p16INK4a, cyclin D1 levels were found to be reduced in Eµ-Myc Wrn−/− lymphomas, particularly late onset lymphomas with high p16INK4a expression (Fig. 4A, asterisk indicates late onset). In addition, proliferation was significantly decreased in the Eµ-Myc Wrn−/− lymphomas (Fig. 4B and C) lymphomas. Consistent with our data from preneoplastic tissue, no elevation of caspase-3–dependent apoptosis was observed in Eµ-Myc Wrn−/− lymphomas (Fig. 4A).

We next assessed the frequency of p53 mutation in lymphomas. The results showed no significant difference in p53 mutation between Eµ-Myc lymphomas (35%) and Eµ-Myc Wrn−/− lymphomas (45%; Supplementary Fig. S3A, *P = 0.748). Furthermore, all tumors with stabilized p53 had mutations in p53, as previously reported (ref. 16; Supplementary Fig. S3B). The tumor suppressor p19ARF was overexpressed in lymphomas with high p53, consistent with its known role in p53 stabilization (ref. 29; Fig. 4A, Supplementary Fig. S3B). Proliferation and apoptosis were assessed next in late onset lymphomas, stratified for mutations in p53, anatomical location, and expression of p16INK4a and p19ARF. These results indicated
that in the context of a p53 mutant background, Wrn deficiency leads to a significant increase in DNA damage (γ-H2AX) and reduces proliferation (phospho-H3) and apoptosis (TUNEL; Supplementary Fig. S4A and S4B). Upon closer examination of p53 mutant tumors, nuclear accumulation of p53 seems more pronounced in Em-Myc Wrn^Dhel/Dhel/lymphomas with a concordant increase in senescence-associated β-galactosidase (Fig. 4B). These results confirmed that a defect in Wrn activity leads to engagement of antiproliferative/senescence pathways, likely through the combined effects of the tumor suppressors p16^ink4a/p19^arf and this does not require wild-type p53.

**Figure 3.** Werner deficiency (Wrn^Dhel/Dhel/) delays lymphomagenesis. A, Kaplan-Meier curves showing disease-free survival of Em-Myc (median survival of 115 days) and Em-Myc Wrn^Dhel/Dhel/ (median survival of 151 days) mice; significant difference via log rank test, P = 0.036. B, flow-cytometry analysis of BrdUrd-positive cells as a measure of proliferation; unpaired t tests, bone marrow: ***P < 0.0001, spleen: ***P = 0.0006. C, flow-cytometry analysis of cleaved caspase-3 as a measure of apoptosis. D, splenic pre-B cells (B220^−/IgM^−) and mature B cells (B220^+/IgM^+) from Em-Myc and Em-Myc Wrn^Dhel/Dhel/ mice; matched littermates (n = 2) from 4-week mice of all genotypes were analyzed in triplicate in panels B, C, and D. E, acidic B-galactosidase staining of germinal center lymphoid follicles from spleens of 4- to 6-week-old mice of the indicated genotype. Images are representative of 3 mice of each genotype. Scale bar represents 40 μm. F, longitudinal analysis of protein levels from splenocytes isolated from mice at 4, 6, and 8 weeks. Antibodies to phospho-histone H2A.X (Serine 139), phospho-Ataxia telangiectasia mutated (Serine 428), phospho-p53 (Serine 18), and p53 were used, and actin is shown as a loading control. WT refers to wild-type control, Wrn refers to Wrn^Dhel/Dhel/, p53^-/- and p53^+/+ to splenocytes isolated from 6-week-old mice, p53^-/- (p19^-/-) mice were irradiated with 5 Gy (137Cs) and splenocytes isolated 2 hours later.
Global gene expression analysis of Wrn-deficient lymphomas identifies TAp63 as a possible mediator of senescence response

To globally define the pathways by which Wrn deficiency impairs tumor development, microarray gene expression analysis was done on 4 lymphomas from each Wrn genotype (Supplementary Table S1, GSE25671). Ingenuity Pathway Analysis, based on known literature connections, of significantly upregulated genes in Wrn-deficient versus Wrn wild-type lymphomas identified genes that centered on the p53 homolog TAp63, the Cdkn2a (p16Ink4a/p19Arf) locus, and the p53-dependent stress-inducible nuclear protein, Trp53inp1 (Fig. 5A, Supplementary Table S1A). TAp63 has recently been recognized as an key mediator of senescence (21). Quantitative RT-PCR confirmed increased expression of TAp63 in additional Eμ-Myc WrnΔhel/Δhel lymphomas (Supplementary Fig. S3). Furthermore, induction of TAp63 was recapitulated in vitro by acute knockdown of Wrn in Eμ-Myc lymphoma-derived cells with p53 mutation (Fig. 5B and Supplementary Fig. S5). In addition, CDK inhibitors such as Cdkn1c (p57Kip2), and Cdkn1b (p27Kip1), were among the upregulated genes in Eμ-Myc WrnΔhel/Δhel lymphomas (GSE25671). All together, the results obtained by global gene expression analysis correlated with the data derived from the immunohistochemical and biochemical assessment of lymphoma tissue and delineate a senescence signature associated with Eμ-Myc WrnΔhel/Δhel lymphomas. In addition, they suggested that TAp63 could be the primary mediator of a senescence response in p53 mutant tumors.

Discussion

The RecQ DNA helicase WRN, has previously been associated with tumor suppression, as Werner Syndrome patients, in addition to premature aging, develop rare mesenchymal tumors late in life (5). In contrast, we hypothesized that WRN, by preventing senescence of cancer cells, could contribute to the tumorigenic process.
This hypothesis was supported by our previous studies showing that the MYC oncoprotein directly stimulates transcription of the WRN gene, and in turn, loss of WRN function leads to senescence of MYC overexpressing cells (1). This codependence of WRN and MYC overexpression was attributed to the role of WRN in limiting replication-associated damage during S-phase, a process that is dramatically accelerated in MYC overexpressing cells through direct association of MYC with the prereplication machinery (2, 3).

To determine whether MYC-driven cancers depend on Wrn in an in vivo setting, we investigated 2 models of Myc-associated tumorigenesis, as well as the effect of both acute and chronic Wrn depletion on tumor growth. The acute depletion of WRN was carried out with NSCLC A549 cells which express high levels of c-MYC and have been optimized for the conditional knockdown of WRN in vivo. In addition, the use of a Myc-driven mouse model allowed us to test the consequences of chronically interfering with a helicase-defective Wrn protein, much like one would envision in a therapeutic setting with small molecule inhibitors to the Wrn helicase domain. Both models showed consistent results, that is, impairment of WRN function profoundly affects tumor growth due to excessive accumulation of DNA damage.

Figure 5. Model of the impact of Wrn depletion in inhibiting Myc-driven tumorigenesis. A, Ingenuity Pathway Analysis network based on known literature connections was built with genes differentially expressed in Wrn deficient and Wrn wild-type lymphomas. Two major nodes emerged from this analysis: CDKN2A and TP63 and only genes linked to these nodes are shown here. Numbers below each icon indicate log2 fold changes expression values in Wrn-deficient versus Wrn wild-type lymphoma. B, relative mRNA expression of TAp63 in Eμ-Myc/p53 mutant cultured lymphoma cells in the presence of shControl or shWrn RNA. Bars represent the mean ± SD (n = 3), statistical analysis was done using unpaired t tests; shWrn#1 (", P = 0.039), shWrn#2 (", P = 0.009) versus shControl. Additional data are shown in Supplementary Fig. S6. Inset: Immunoblot of WRN protein in same samples. C, model of delayed Eμ-Myc lymphomagenesis caused by Wrn deficiency. Eμ-Myc expression triggers preneoplastic proliferation but also engages endogenous tumor suppressors p53 and p19ARF. In the absence of functional Wrn, Myc-induced replication stress is exacerbated, causing DNA damage, which hyperactivates multiple tumor suppressor pathways, impairs proliferation of tumor cells, and delays appearance of lymphomas.
damage and decreased proliferation with consequent senescence (observed in the Eμ-Myc lymphoma) or prominent necrosis (as observed in the A459 xenograft model). Wrn helicase deficiency effectively delayed the insurgence of lymphomas through activation of 2 tumor suppressors: p16^{Ink4a} and TAp63 (see model in Fig. 5C). Importantly, we were able to recapitulate in lymphoma cells from Eμ-Myc mice that acute deletion of Wrn also induces TAp63, even in a p53 mutant setting (Fig. 5 and Supplementary Fig. S5). Our results are consistent with a recent report of increased senescence and delayed lymphomagenesis in Eμ-Myc p53^{129C/C} and Eμ-Myc p53^{129C/129C} mutant mice relative to Eμ-Myc p53^{+/−} mice (30) and highlight a mechanism of growth arrest and cellular senescence that has relevance for future therapeutic application of WRN inhibitors even in the context of p53 mutant cancers. In this view, the endogenous DNA damage generated by Wrn deficiency acts not unlike the damage generated via genotoxic treatment or telomere shorting to engage tumor suppressor pathways (31, 32). The effect of Wrn depletion was lost in p53-deficient backgrounds (3), and Wrn deficiency increased the rate of cancer in a p53-deficient background (33), suggesting that complete loss of function of p53 could disable the senescence response in Wrn-deficient cancer cells. Additional model systems will be needed to distinguish the impact of p53 deletion versus mutation on Wrn function.

It is worthwhile to note that the Kaplan–Meier curves comparing Eμ-Myc Wrn wild type with Wrn^{−/−} indicated an age-dependent penetrance of tumor suppression caused by Wrn deficiency. Although this requires further investigation, one hypothesis that is consistent with the observed elevation of p16^{Ink4a} in Wrn-deficient tumors is that Wrn deficiency, superimposed with the natural aging of hematopoietic precursors (also characterized by an elevation of p16^{Ink4a}), may additively provide a barrier for late onset tumor development (34). A second hypothesis is derived from the report that late onset lymphomas in Eμ-Myc mice are distinct from early onset tumors with respect to differentiation status and signaling pathways, such as those regulated by NF-XB (35). Differential activation of these pathways may modify the impact of Wrn deficiency on engaging antiproliferative pathways.

Our studies also highlight the differential sensitivity of cancer cells versus normal cells to loss of WRN. This is reminiscent of other reports of tumor-specific sensitivity to loss of DNA repair function. For example, mice deficient in NHEJ activity due to mutation in Prkdc (the catalytic subunit of DNA-dependent protein kinase) are normal, barring a defect in V(D)J recombination. However, they are markedly resistant to development of squamous cell carcinoma, indicating active NHEJ is necessary for optimal tumor growth (36). Furthermore, a recent study indicates that Atr deficiency also protects mice from Myc-driven lymphomas (37). In contrast, Atm deficiency by eliminating a DNA damage–induced apoptotic response accelerates Myc-driven tumorigenesis (38), highlighting differences in DNA damage pathways and their relation to Myc. This principle of differential sensitivity of cancer versus normal cells to DNA repair deficiency has important therapeutic potential, as in the case of use of PARP inhibitors for cancers deficient in BRCA1 or BRCA2 function (39). Similarly, therapeutics directed against RecQ helicases may prove beneficial for cancers with amplification/alterations of MYC by marshaling the DNA damage response and intrinsic tumor suppressor pathways. Our experiments directly addressed the effects of a WRN helicase mutant in tumor growth, thus pinpointing not just the gene, but also the domain that could be targeted by small molecules. The catalytic activity of this domain necessitates both ATP binding and ATPase activity (4) and, as such, is highly druggable (40). Thus, targeting WRN or its enzymatic functions could prove to be an effective strategy to treat MYC-associated cancers.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: R. Moser, M. Toyoshima, C.J. Kemp, C. Grandori Development of methodology: R. Moser, M. Toyoshima, K.E. Gurlay, C.J. Kemp Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R. Moser, M. Toyoshima, K. Robinson, K.E. Gurlay Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R. Moser, M. Toyoshima, J. Davison, M. Morgan, C.J. Kemp, C. Grandori Writing, review, and/or revision of the manuscript: R. Moser, M. Toyoshima, K. Robinson, H.L. Howie, J. Davison, C.J. Kemp, C. Grandori Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R. Moser, M. Toyoshima, K. Robinson Study supervision: C.J. Kemp, C. Grandori

Acknowledgments
The authors thank Dr. Ray Monnat and Dr. Julia Sidorova for critically reviewing the manuscript, Dr. Denise Galloway and her laboratory for support and guidance during the course of this work, Dr. Patrick Pippion and Dr. Daity Miller for viral vectors utilized for Wrn knockdown experiments, and Dr. C.A. Schmit for retroviral infection protocols and advice.

Grant Support
This work was supported by R01 grants NIA AG02661, NCI CA099517, and the NCI Mouse Models of Human Cancer Consortium. J. Davison and M. Morgan were supported in part by NIH P30 CA051704. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1754 solely to indicate this fact.

Received October 20, 2011; revised January 25, 2012; accepted January 26, 2012; published OnlineFirst February 1, 2012.

References


5. Rossi ML, Ghosh AK, Bohr VA. Roles of Werner syndrome protein in protection of genome integrity. DNA Repair (Amst) 2010;9:331–44.


